Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:CABA NASDAQ:CASI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.58-0.9%$1.48$1.18▼$2.70$419.17M1.931.74 million shs690,477 shsCABACabaletta Bio$3.38-6.5%$3.17$1.26▼$4.23$375.71M3.183.27 million shs1.09 million shsCASICASI Pharmaceuticals$0.21$0.21$0.21▼$3.09$2.55M0.91482,532 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-7.02%-0.93%+7.43%+13.57%+30.33%CABACabaletta Bio+0.56%-9.75%+10.74%+28.93%+177.69%CASICASI Pharmaceuticals0.00%+0.00%+0.00%-75.59%-89.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.58-0.9%$1.48$1.18▼$2.70$419.17M1.931.74 million shs690,477 shsCABACabaletta Bio$3.38-6.5%$3.17$1.26▼$4.23$375.71M3.183.27 million shs1.09 million shsCASICASI Pharmaceuticals$0.21$0.21$0.21▼$3.09$2.55M0.91482,532 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-7.02%-0.93%+7.43%+13.57%+30.33%CABACabaletta Bio+0.56%-9.75%+10.74%+28.93%+177.69%CASICASI Pharmaceuticals0.00%+0.00%+0.00%-75.59%-89.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.89Moderate Buy$8.75455.56% UpsideCABACabaletta Bio 2.63Moderate Buy$15.14348.68% UpsideCASICASI Pharmaceuticals 2.00Hold$4.001,827.71% UpsideCurrent Analyst Ratings BreakdownLatest CASI, AUTL, and CABA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.005/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AUTLAutolus Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/9/2026AUTLAutolus Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/31/2026AUTLAutolus Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$12.00 ➝ $10.003/27/2026AUTLAutolus Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/25/2026AUTLAutolus Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/24/2026CABACabaletta Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $16.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$75.39M5.56N/AN/A$0.67 per share2.35CABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/ACASICASI Pharmaceuticals$26.85M0.10N/AN/A$0.12 per share1.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$287.53M-$1.08N/AN/AN/A-381.40%-99.05%-42.31%N/ACABACabaletta Bio-$167.86M-$2.28N/AN/AN/AN/A-121.73%-90.19%N/ACASICASI Pharmaceuticals-$39.26M-$3.01N/AN/AN/A-183.93%N/A-131.54%N/ALatest CASI, AUTL, and CABA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 million3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/ACASICASI PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A5.945.48CABACabaletta BioN/A2.772.77CASICASI PharmaceuticalsN/A0.300.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CABACabaletta BioN/ACASICASI Pharmaceuticals22.23%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CABACabaletta Bio6.44%CASICASI Pharmaceuticals21.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCABACabaletta Bio50111.32 million104.16 millionOptionableCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableCASI, AUTL, and CABA HeadlinesRecent News About These CompaniesCASI Pharmaceuticals stock plunges on Nasdaq delisting noticeFebruary 26, 2026 | za.investing.comWhat Drove CASI Pharmaceuticals' 24% Rise After Hours?February 26, 2026 | msn.comCASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings PanelFebruary 25, 2026 | accessnewswire.comACASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts SalesJanuary 24, 2026 | theglobeandmail.comCASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated RejectionJanuary 15, 2026 | finanznachrichten.deCASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)January 15, 2026 | accessnewswire.comACASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune ThrombocytopeniaJanuary 12, 2026 | accessnewswire.comACASI Pharmaceuticals wins Nasdaq listing extension to February 2026December 23, 2025 | msn.comCASI Pharmaceuticals stock surges after Nasdaq grants listing extensionDecember 23, 2025 | za.investing.comCASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing RequirementsDecember 23, 2025 | accessnewswire.comACASI Pharmaceuticals Announces Up to $20 Million Convertible Note FinancingDecember 11, 2025 | accessnewswire.comACASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual MeetingDecember 9, 2025 | finanznachrichten.deCasi Pharmaceuticals announces CID-103 immune thrombocytopenia study resultsDecember 8, 2025 | msn.comCASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual MeetingDecember 8, 2025 | accessnewswire.comACASI Pharmaceuticals Announces Changes in Board GovernanceNovember 19, 2025 | accessnewswire.comACASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial ResultsNovember 14, 2025 | accessnewswire.comACASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQNovember 10, 2025 | accessnewswire.comACASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation ConferenceNovember 4, 2025 | accessnewswire.comACASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual MeetingNovember 3, 2025 | accessnewswire.comACasi Pharmaceuticals appoints James Hunag to board of directorsSeptember 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCASI, AUTL, and CABA Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.58 -0.02 (-0.94%) As of 12:13 PM Eastern This is a fair market value price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Cabaletta Bio NASDAQ:CABA$3.38 -0.24 (-6.51%) As of 12:14 PM Eastern This is a fair market value price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.CASI Pharmaceuticals NASDAQ:CASI$0.21 0.00 (0.00%) As of 05/14/2026CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Dividend Growth or High Yield: The Income Investor's Bet Karman: Defense Darling's Outlook Strengthens After 40% Drop Nebius Upside Expands as AI Feedback Loop Intensifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
